Cohen Ramon, Ostrovsky Viviana, Zornitzki Lior, Elbirt Daniel, Zornitzki Taiba
Internal Medicine Department B, Kaplan Medical Center, Hebrew University Medical School, Rehovot 76100, Israel.
Department of Clinical Immunology, Allergy, and AIDS, Kaplan Medical Center, Hebrew University Medical School, Rehovot 76100, Israel.
Microorganisms. 2025 Mar 28;13(4):773. doi: 10.3390/microorganisms13040773.
Hypercalcemia represents a rare complication of nontuberculous Mycobacterium (NTM) infections, particularly in individuals with human immunodeficiency virus (HIV) positivity. This systematic review examines NTM infections associated with hypercalcemia, including the presentation of a novel and illustrative case of . A meticulous literature search identified 24 cases relevant to this phenomenon (11 HIV-positive and 13 non-HIV), which were included in the analysis. Key clinical and laboratory findings reveal significant contrasts between HIV-positive and non-HIV patients. In the HIV-positive cohort, hypercalcemia is commonly developed after the initiation of highly active antiretroviral therapy (HAART) or treatment for NTM infections despite severe underlying immunosuppression. Conversely, in the non-HIV group, a spectrum of immunosuppressive conditions, including chronic renal failure and prolonged use of immunosuppressive drugs, was implicated in the pathogenesis of NTM infections with hypercalcemia. Two distinct mechanistic pathways likely underlie this association. In HIV-positive patients, immune restoration following HAART appears to drive granuloma formation and excessive 1,25-dihydroxyvitamin D production. In non-HIV individuals, prolonged immune suppression may facilitate macrophage activation associated with NTM infections, thereby contributing to hypercalcemia. Treatment strategies varied and included bisphosphonates, corticosteroids, and hemodialysis. Notably, bisphosphonates emerged as a safe and effective option in most cases. Antibiotic therapy was deemed unnecessary when hypercalcemia was the sole symptom of NTM infection. This review underscores the importance of recognizing hypercalcemia as a potential complication of NTM infections and tailoring management strategies to the patient's underlying immunological status.
高钙血症是非结核分枝杆菌(NTM)感染的一种罕见并发症,尤其在人类免疫缺陷病毒(HIV)阳性个体中。本系统评价研究了与高钙血症相关的NTM感染,包括一个新颖且具说明性的病例。经过细致的文献检索,确定了24例与该现象相关的病例(11例HIV阳性和13例非HIV阳性),并纳入分析。关键的临床和实验室检查结果显示,HIV阳性和非HIV阳性患者之间存在显著差异。在HIV阳性队列中,尽管存在严重的基础免疫抑制,但高钙血症通常在开始高效抗逆转录病毒治疗(HAART)或治疗NTM感染后出现。相反,在非HIV组中,一系列免疫抑制状况,包括慢性肾衰竭和长期使用免疫抑制药物,与伴有高钙血症的NTM感染发病机制有关。这种关联可能有两种不同的机制途径。在HIV阳性患者中,HAART后的免疫恢复似乎促使肉芽肿形成和1,25 - 二羟维生素D过度产生。在非HIV个体中,长期免疫抑制可能促进与NTM感染相关的巨噬细胞活化,从而导致高钙血症。治疗策略各不相同,包括双膦酸盐、皮质类固醇和血液透析。值得注意的是,在大多数情况下,双膦酸盐是一种安全有效的选择。当高钙血症是NTM感染的唯一症状时,抗生素治疗被认为不必要。本综述强调了认识到高钙血症是NTM感染潜在并发症的重要性,并根据患者的基础免疫状态制定管理策略。